EP0959885A4 - Imidazoles a substitution triaryle et leurs procedes d'utilisation - Google Patents

Imidazoles a substitution triaryle et leurs procedes d'utilisation

Info

Publication number
EP0959885A4
EP0959885A4 EP97948327A EP97948327A EP0959885A4 EP 0959885 A4 EP0959885 A4 EP 0959885A4 EP 97948327 A EP97948327 A EP 97948327A EP 97948327 A EP97948327 A EP 97948327A EP 0959885 A4 EP0959885 A4 EP 0959885A4
Authority
EP
European Patent Office
Prior art keywords
methods
substituted imidazoles
triaryl substituted
triaryl
imidazoles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97948327A
Other languages
German (de)
English (en)
Other versions
EP0959885A1 (fr
Inventor
Linda L Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9700559.9A external-priority patent/GB9700559D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0959885A1 publication Critical patent/EP0959885A1/fr
Publication of EP0959885A4 publication Critical patent/EP0959885A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP97948327A 1996-11-20 1997-11-17 Imidazoles a substitution triaryle et leurs procedes d'utilisation Withdrawn EP0959885A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3146896P 1996-11-20 1996-11-20
US31468P 1996-11-20
GBGB9700559.9A GB9700559D0 (en) 1997-01-13 1997-01-13 Triaryl substituted imidazoles and methods of use
GB9700559 1997-01-13
PCT/US1997/020955 WO1998022108A1 (fr) 1996-11-20 1997-11-17 Imidazoles a substitution triaryle et leurs procedes d'utilisation

Publications (2)

Publication Number Publication Date
EP0959885A1 EP0959885A1 (fr) 1999-12-01
EP0959885A4 true EP0959885A4 (fr) 2002-07-17

Family

ID=26310784

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97948327A Withdrawn EP0959885A4 (fr) 1996-11-20 1997-11-17 Imidazoles a substitution triaryle et leurs procedes d'utilisation

Country Status (5)

Country Link
EP (1) EP0959885A4 (fr)
JP (1) JP2001504489A (fr)
AU (1) AU726311B2 (fr)
CA (1) CA2271941A1 (fr)
WO (1) WO1998022108A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
EP1743655B1 (fr) 2000-01-21 2014-06-25 Novartis AG Combinaisons à base d'inhibiteurs de DPP-IV et d'antidiabetiques
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6821960B2 (en) 2000-11-17 2004-11-23 Noyo Nordisk Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
WO2002040445A1 (fr) 2000-11-17 2002-05-23 Novo Nordisk A/S Agonistes de glucagon/antagonistes inverses
US6706744B2 (en) 2000-11-17 2004-03-16 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO2003024447A1 (fr) * 2001-09-20 2003-03-27 Smithkline Beecham Corporation Inhibiteurs de glycogene synthase kinase-3
JP2005507932A (ja) * 2001-10-12 2005-03-24 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満の処置のためのフェニル置換５−員窒素含有複素環
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
WO2004058727A1 (fr) * 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation 3,5-dihydro-4-h-imidazol-4-ones substitues utilises dans le traitement de l'obesite
AU2004210127B2 (en) 2003-01-27 2009-10-01 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
CA2547785A1 (fr) 2003-12-19 2005-07-21 Merck & Co., Inc. Guanidines cycliques, compositions contenant de tels composes et procedes d'utilisation
NZ551405A (en) 2004-06-04 2009-06-26 Merck & Co Inc Pyrazole derivatives, compositions containing such compounds and methods of use
CN1980665A (zh) 2004-07-07 2007-06-13 默克公司 吡唑酰胺衍生物，包含这些化合物的组合物和使用方法
WO2006014618A2 (fr) 2004-07-22 2006-02-09 Merck & Co., Inc. Pyrazoles substitues, compositions contenant de tels composes et leurs methodes d'utilisation
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
JP2008534593A (ja) 2005-03-30 2008-08-28 メルク エンド カムパニー インコーポレーテッド グルカゴン受容体アンタゴニスト化合物、そのような化合物を含む組成物、及びその使用方法
CN101300232A (zh) 2005-07-26 2008-11-05 默克公司 合成取代的吡唑的方法
PT1931350E (pt) 2005-09-14 2014-02-12 Takeda Pharmaceutical Administração de inibidores de dipeptidil peptidase
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
US7989472B2 (en) 2006-03-23 2011-08-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US7935713B2 (en) 2006-05-16 2011-05-03 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2011041293A1 (fr) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Dérivés pyrazolo [1, 5—a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
PL2531501T3 (pl) 2010-02-03 2014-05-30 Takeda Pharmaceuticals Co Inhibitory kinazy 1 regulującej sygnał apoptotyczny
EP3065736B1 (fr) 2013-11-04 2018-11-14 Merck Sharp & Dohme Corp. Composés antagonistes du récepteur du glucagon, compositions correspodantes et méthodes d'utilisation
EP3102207B1 (fr) * 2014-02-07 2022-05-11 Agency For Science, Technology And Research Inhibiteurs de la caséine kinase 1 à base d'azole 2,4,5-tri-substitué en tant qu'inducteurs de la cardiomyogenèse
WO2016141381A2 (fr) * 2015-03-05 2016-09-09 University Of Notre Dame Du Lac Potentialisateurs d'antibiotiques bêta-lactames
US11958828B1 (en) 2023-11-07 2024-04-16 King Faisal University 4,5-bis(4-bromophenyl)-1-hexyl-2-(3-pyridyl)-1H-imidazole as an antimicrobial compound
US12180169B1 (en) 2023-12-28 2024-12-31 King Faisal University 4-[4,4-bis(4-bromophenyl)-5-oxo-2-thioxoimidazolidin-1-yl]butanoic acid as an antimicrobial compound
US11993575B1 (en) 2023-12-29 2024-05-28 King Faisal University Ethyl [4,4-bis(4-bromophenyl)-2,5-dioxoimidazolidin-1-yl]acetate as an antimicrobial compound
US12180167B1 (en) 2024-01-02 2024-12-31 King Faisal University 6-[4,4-bis(4-bromophenyl)-2,5-dioxoimidazolidin-1-yl]hexanoic acid as an antimicrobial compound
US12180168B1 (en) 2024-01-02 2024-12-31 King Faisal University 3-[4,4-bis(4-nitrophenyl)-2,5-dioxoimidazolidin-1-yl]propanoic acid as an antimicrobial compound
US11970462B1 (en) 2024-01-03 2024-04-30 King Faisal University Ethyl 3-[4,4-bis(4-chlorophenyl)-2,5-dioxoimidazolidin-1-yl]propanoate as an antimicrobial compound

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929807A (en) * 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US4430326A (en) * 1981-12-22 1984-02-07 University Patents, Inc. Method of diminishing glucose levels resulting from endogenous glucagon
WO1993014081A1 (fr) * 1992-01-13 1993-07-22 Smithkline Beecham Corporation Derives imidazole et leur utilisation comme inhibiteurs de cytokine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) * 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929807A (en) * 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US4430326A (en) * 1981-12-22 1984-02-07 University Patents, Inc. Method of diminishing glucose levels resulting from endogenous glucagon
WO1993014081A1 (fr) * 1992-01-13 1993-07-22 Smithkline Beecham Corporation Derives imidazole et leur utilisation comme inhibiteurs de cytokine

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANESTEZIOLOGIIA I REANIMATOLOGIIA. RUSSIA 1996 SEP-OCT, no. 5, September 1996 (1996-09-01), pages 29 - 39, ISSN: 0201-7563 *
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS. UNITED STATES 1 FEB 1993, vol. 300, no. 2, 1 February 1993 (1993-02-01), pages 747 - 750, ISSN: 0003-9861 *
DATABASE MEDLINE [online] 1 February 1993 (1993-02-01), UNSON C G ET AL: "The role of histidine-1 in glucagon action.", XP002199270, Database accession no. NLM8382034 *
DATABASE MEDLINE [online] 1996, DEL REY A ET AL: "Metabolic and endocrine effects of interleukin-1 in obese, diabetic Zucker fa/fa rats.", XP002199269, Database accession no. NLM8886749 *
DATABASE MEDLINE [online] September 1996 (1996-09-01), MAYER N A ET AL: "The utilization of nutrient substances during wound healing", XP002199268, Database accession no. NLM9027251 *
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES: OFFICIAL JOURNAL, GERMAN SOCIETY OF ENDOCRINOLOGY [AND] GERMAN DIABETES ASSOCIATION. GERMANY 1996, vol. 104, no. 4, 1996, pages 317 - 326, ISSN: 0947-7349 *
See also references of WO9822108A1 *

Also Published As

Publication number Publication date
AU5441498A (en) 1998-06-10
WO1998022108A1 (fr) 1998-05-28
AU726311B2 (en) 2000-11-02
CA2271941A1 (fr) 1998-05-28
JP2001504489A (ja) 2001-04-03
EP0959885A1 (fr) 1999-12-01

Similar Documents

Publication Publication Date Title
EP0959885A4 (fr) Imidazoles a substitution triaryle et leurs procedes d'utilisation
EP1047347A4 (fr) Electrodes a nervures et leurs procedes d'utilisation
EP1027066A4 (fr) Complexes mhc solubles et procedes d'utilisation desdits complexes
EP0789553A4 (fr) Compositions deodorantes, antimicrobiennes et conservatrices et leurs procedes d'utilisation
NO995247D0 (no) Benyttelse av utstyr i et brönnsystem
EP0880356A4 (fr) Peptides antimicrobiens et procedes d'utilisation associes
EP0856155A4 (fr) Compositions de marquage fluorescentes et luminescentes et leurs procedes d'utilisation
EP0918534A4 (fr) Promedicaments peptidyl et leurs procedes de fabrication et d'utilisation
EP1227821A4 (fr) Compositions therapeutiques et leurs procedes d'utilisation
EP1037911A4 (fr) Systeme anti-pathogene et procedes d'utilisation
DE69622971D1 (de) Variabler "Linear-in-Dezibel" Verstärker
DE69522528D1 (de) Kathetereinfuehrsystem
DE69531544D1 (de) Kathetersystem
DE69535919D1 (de) Kathetersystem
EP0910301A4 (fr) Compositions et procedes d'enrobage de dispositifs medicaux
IT1273546B (it) Apparecchiatura radiodiagnostica
FI964973A7 (fi) Kalanterointijärjestelmä
DE69503688D1 (de) Kabelbinder
EP0796079A4 (fr) Compositions solides a base de silicone et leurs procedes de fabrication et d'utilisation
FR2674864B1 (fr) Bande adhesive facilement transferable et procedes d'utilisation et de fabrication.
EP1076565A4 (fr) Analogues d'indolicidine et leurs procedes d'utilisation
EP1056457A4 (fr) Compositions de s-lansoprazole et procedes d'utilisation
EP1240201A4 (fr) Apolipoproteines oxydees et leurs procedes d'utilisation
EP0888267A4 (fr) Nouveaux composes de pyruvate et procedes d'utilisation
EP1147126A4 (fr) Cofacteurs pour facteurs trophiques et procedes d'utilisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990621

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020604

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 9/12 B

Ipc: 7A 61P 3/10 B

Ipc: 7A 61P 3/04 B

Ipc: 7A 61K 31/44 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030904